Morning, Marco. Dengue took another step up the Gulf coast overnight — Pasco County now — and Medicare's $50 obesity-drug pilot turns out to be moving a lot faster than anyone budgeted for, which means new GLP-1 starts are already showing up in your admissions. Also a quietly excellent essay about the patients nobody screens. Coffee, then sleep.
A · Top Stories
Update · Dengue
Pasco County confirms a dengue case — the Gulf-coast band keeps widening
DOH-Pasco issued an updated mosquito-borne illness advisory Wednesday morning confirming a human dengue case, with the county health department and Pasco Mosquito Control coordinating surveillance and source reduction. That follows Citrus on Monday and the Hillsborough–Pinellas signals reported Tuesday, on top of the earlier Miami-Dade and Palm Beach clusters. Florida is now well past the point where this reads as a handful of unrelated introductions; the state's local-transmission footprint has moved steadily north along the Gulf coast through August, and the serotype pattern in Hillsborough points to sustained local circulation rather than repeated travel-linked seeding.
Why it matters to you: Pasco is roughly three hours up I-75. The practical change isn't the case count, it's that a negative travel history has stopped narrowing your differential on this coast. In an elderly admit the tell is a cluster you'd otherwise pin on something else — fever with a dropping platelet count, a rising hematocrit, and a transaminase bump. The dangerous window is defervescence, not the fever, which is exactly when the ED is inclined to think the patient is turning the corner. NSAID choices and prophylactic anticoagulation both change if dengue is live on your list.
Action: dengue is a reportable condition in Florida — know whether your ED or your hospitalist group owns the DOH notification, because it's supposed to go out the next business day and that's the kind of thing that quietly falls between two services at 3 a.m.
DOH-Pasco advisory (Aug 26) · WUSF on Hillsborough/Pinellas · CDC dengue data
Medicare · GLP-1s
Medicare's $50 obesity-drug pilot is scaling faster than expected — and half the patients are new to GLP-1s
NPR reported Wednesday afternoon that CVS and Walgreens have each filled roughly 100,000 prescriptions under Medicare's GLP-1 Bridge program since it opened July 1 — call it 200,000 at two chains alone, in under two months. Walmart says Bridge prescriptions are now processing at more than 5,000 Walmart and Sam's Club pharmacies and growing week over week. CMS administrator Mehmet Oz said in late July that 250,000 beneficiaries had signed up. Medicare had estimated about 4 million people would qualify, so this is somewhere in the 5–10% range of the eligible pool already. KFF puts the 18-month tab somewhere between $1.3 billion and $10 billion; CMS hasn't published its own estimate. The detail that should catch your eye is from Walgreens' chief pharmacy officer Rick Gates: about half of the patients they've served under Bridge had never taken a GLP-1 before.
Why it matters to you: that's a large, sudden cohort of Medicare-age patients starting semaglutide or tirzepatide for the first time, and they will land on your service. Three things follow. Retained gastric contents in a GLP-1-naive patient is a real aspiration risk if anyone takes them to endoscopy or the OR — and the anesthesiologist's first question will be the last dose date, not the drug name. Early-titration nausea, vomiting and poor intake in an 80-year-old on an ACE inhibitor and a diuretic is a straightforward path to prerenal AKI, and the med list will look "clean" if nobody flags the new injectable. And the exclusion rules are counterintuitive enough to cause discharge problems: Bridge's $50 price applies only to people using the drug purely for weight loss, so an estimated 5.9 million beneficiaries who have type 2 diabetes or moderate-to-severe sleep apnea get routed back to their Part D plan, sometimes at hundreds of dollars a month.
Action: ask pharmacy whether your admission med rec captures a GLP-1 last dose date rather than just "on semaglutide." One field, and it answers the NPO question before anesthesia has to page you.
NPR (Aug 26) · NPR on the exclusions · KFF explainer · CMS provider page
Geriatrics
The patients nobody screens: cancer guidelines stop at the nursing-home door
Kim Johnson, a cancer epidemiologist at Washington University in St. Louis, wrote in STAT on Tuesday about her aunt — 78, living in a long-term care facility since 2020, non-ambulatory from arthritis but sharp, social, running the residents' council. Her stage 4 breast cancer was found incidentally while she was hospitalized for a UTI. She died three weeks later. She had a palpable lump she never mentioned, and she had not been screened once in six years at the facility. Johnson's point isn't that everyone in a nursing home should get a mammogram — it's that there is no major national screening guideline written for this population at all, that the literature dwells heavily on the harms of screening LTC residents and barely at all on identifying the subset who'd still benefit, and that median survival after LTC admission (about 2.2 years in one study) is a poor guide for someone admitted for arthritis rather than a terminal illness. The tumor was ER-positive. Caught earlier, it was the kind of disease that hormone therapy holds for years.
Why it matters to you: the incidental discovery happened during a hospitalization for something else — which is to say, it happened to a hospitalist. You are routinely the first physician to lay hands on an LTC resident in months or years, and the admission exam is where a lump, a mass, or blood that nobody has evaluated actually surfaces. There's no guideline to lean on, which means whatever you document and communicate back to the facility is the plan.
Action: if you find something on an LTC patient, write the shared-decision conversation into the discharge summary explicitly — what was found, what the patient said they'd want, what follow-up was recommended. It's the only way it survives the trip back to the facility.
STAT First Opinion — Kim Johnson · USPSTF breast screening (insufficient evidence ≥75)